Use of darbepoetin alfa (Aranesp) in pediatric kidney disease

被引：0
|
作者：
McTaggart, S.
Alexander, S.
Craig, J.
Henning, P.
Hodson, E.
Jones, C.
Jureidini, F.
Lewis, D.
Powell, H.
Burke, J.
机构：
[1] Royal Childrens Hosp, Child & Adolescent Renal Serv, Brisbane, Qld, Australia
[2] Univ Queensland, Mater Childrens Hosp, Child & Adolescent Renal Serv, Brisbane, Qld 4101, Australia
[3] Childrens Hosp Westmead, Dept Nephrol, Sydney, NSW, Australia
[4] Royal Childrens Hosp, Dept Nephrol, Melbourne, Vic, Australia
来源：
PEDIATRIC NEPHROLOGY | 2007年 / 22卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：1472 / 1472
页数：1
相关论文
共 50 条
  • [41] Aranesp™ (darbepoetin alfa) administered once every other week (Q2W) corrects anemia in patients with chronic kidney disease (CKD)
    Lindberg, JS
    Navarro, J
    Suranyi, M
    Walker, R
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (04) : A22 - A22
  • [42] Novel erythropoiesis stimulating protein -: NESP -: Darbepoetin alfa -: ARANESP® -: Hematopoietic -: Antianemic -: Oncolytic
    不详
    DRUGS OF THE FUTURE, 2001, 26 (03) : 304 - 305
  • [43] Extended dosing with darbepoetin alfa in patients with chronic kidney disease on hemodialysis
    Amico, Patrizia
    Dickenmann, Michael
    Steiger, Juerg
    Saldutto, Biagio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 154 - 154
  • [44] Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease
    Uemura, Osamu
    Hattori, Motoshi
    Hataya, Hiroshi
    Ito, Shuichi
    Ito, Naoko
    Akizawa, Tadao
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (06) : 932 - 938
  • [45] Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease
    Hudson, JQ
    Sameri, RM
    PHARMACOTHERAPY, 2002, 22 (09): : 141S - 149S
  • [46] EPOETIN ALFA AND DARBEPOETIN ALFA COSTS BY DOMINANT DOSING INTERVAL IN CHRONIC KIDNEY DISEASE NOT ON DIALYSIS
    Bailey, Robert
    Tunceli, Ozgur
    Singer, Joseph
    Stephenson, Judith
    Senbetta, Mekre
    McKenzie, Scott
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (04) : A23 - A23
  • [47] Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease
    Osamu Uemura
    Motoshi Hattori
    Hiroshi Hataya
    Shuichi Ito
    Naoko Ito
    Tadao Akizawa
    Clinical and Experimental Nephrology, 2014, 18 : 932 - 938
  • [48] A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
    Pfeffer, Marc A.
    Burdmann, Emmanuel A.
    Chen, Chao-Yin
    Cooper, Mark E.
    de Zeeuw, Dick
    Eckardt, Kai-Uwe
    Feyzi, Jan M.
    Ivanovich, Peter
    Kewalramani, Reshma
    Levey, Andrew S.
    Lewis, Eldrin F.
    McGill, Janet B.
    McMurray, John J. V.
    Parfrey, Patrick
    Parving, Hans-Henrik
    Remuzzi, Giuseppe
    Singh, Ajay K.
    Solomon, Scott D.
    Toto, Robert
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21): : 2019 - 2032
  • [49] Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease
    Agarwal, Anil K.
    EXPERT OPINION ON DRUG SAFETY, 2009, 8 (02) : 145 - 153
  • [50] Aranesp® (darbepoetin alfa) administered every other week (Q2W) corrects and maintains hemoglobin (Hb) in chronic kidney disease (CKD) patients
    Hertel, J
    Locay, H
    Scarlata, D
    Prathikanti, R
    Audhya, P
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A31 - A31
12345